A Phase 1, Open-label, Single-dose, Randomized, 4-treatment, 4- Period, Crossover, Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bza/Conjugated Estrogens in Healthy Postmenopausal Women

Trial Profile

A Phase 1, Open-label, Single-dose, Randomized, 4-treatment, 4- Period, Crossover, Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bza/Conjugated Estrogens in Healthy Postmenopausal Women

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Bazedoxifene (Primary) ; Conjugated estrogens/bazedoxifene
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jan 2013 Actual initiation date changed from Jul 2012 to Aug 2012 as reported by ClinicalTrials.gov.
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top